Patients with type 2 diabetes or obesity who meet criteria for GLP-1 therapy may experience additional lipid benefits, particularly those with mixed dyslipidaemia, metabolic syndrome, or established cardiovascular disease
5,6 Nutrients associated with GLP1 secretion are monosaccharides, long-chain fatty acids and short-chain fatty acids (from bacterial fiber fermentation)
The main drug class of GLP-1 receptor agonist is liraglutide, dulaglutide, lixisenatide, and others
Patents expire starting in 2026 in countries like India, China, Brazil and Canada
However, in our study, oxidative stress-induced cell death was triggered by lipid peroxidation instead of the canonical mitochondrial ROS accumulation